Edition:
United States

Hemispherx Biopharma Inc (HEB)

HEB on American Stock Exchange

0.33USD
23 Oct 2017
Change (% chg)

$0.00 (+1.54%)
Prev Close
$0.32
Open
$0.33
Day's High
$0.33
Day's Low
$0.32
Volume
86,728
Avg. Vol
306,570
52-wk High
$1.15
52-wk Low
$0.30

Latest Key Developments (Source: Significant Developments)

Hemispherx Biopharma says files for resale of 5.4 mln shares of common stock, offered for sale by selling stockholders
Friday, 29 Sep 2017 05:42pm EDT 

Sept 29 (Reuters) - Hemispherx Biopharma Inc :Hemispherx Biopharma - files for resale of of 5.4 million shares of common stock, offered for sale by selling stockholders - SEC Filing‍​.  Full Article

Hemispherx Biopharma Co's board has reviewed financial condition of company and anticipated needs of company to pursue its goals
Tuesday, 29 Aug 2017 09:07am EDT 

Aug 29 (Reuters) - Hemispherx Biopharma Inc :Co's board has reviewed financial condition of company and anticipated needs of company to pursue its goals.Hemispherx Biopharma - Determined that co will need to find additional funding sources and reduce on-going expenses to cover expenses and pursue goals.Hemispherx Biopharma - On Aug 22, board authorized executive compensation deferral plan, employee pay reduction plan, directors compensation deferral plan.  Full Article

Hemispherx Biopharma announces quarterly loss per share $0.11
Monday, 15 May 2017 05:24pm EDT 

May 15 (Reuters) - Hemispherx Biopharma Inc :Hemispherx Biopharma announces financial results for the three months ended March 31, 2017.Quarterly loss per share $0.11.Hemispherx Biopharma- Have begun to generate and can now reasonably project growing future revenues from newly manufactured lots of ampligen for 2017.Hemispherx Biopharma - Bridge loan established on May 12 to assist in funding expenses of manufacturing Ampligen to generate revenues for 2017, 2018.Hemispherx Biopharma Inc - Cash, cash equivalents and marketable securities were about $3.7 million at March 31, 2017 versus $5.9 million as of Dec 31, 2016.  Full Article

Hemispherx Biopharma announces identification of high responder patient subgroup from Ampligen Phase III trial
Monday, 31 Oct 2016 08:30am EDT 

Hemispherx Biopharma Inc :Hemispherx Biopharma announces identification of high responder patient subgroup from Ampligen phase III trial in patients with CFS/ME.  Full Article

Sabby Management LLC reports 6.92 pct passive stake in Hemispherx Biopharma
Thursday, 1 Sep 2016 01:52pm EDT 

Hemispherx Biopharma Inc :Sabby Management LLC reports 6.92 percent passive stake in Hemispherx Biopharma Inc as of August 31 - Sec Filing.  Full Article

Hemispherx says focusing on commercial success by seeking co-development partners
Monday, 15 Aug 2016 05:03pm EDT 

Hemispherx Biopharma Inc : Hemispherx biopharma announces financial results for the six months ended june 30, 2016 .Says now focusing on commercial success by seeking co-development partners.  Full Article

Hemispherx, Avrio strike contract manufacturing deal
Wednesday, 27 Jul 2016 08:30am EDT 

Hemispherx Biopharma Inc : Agreement with Avrio Biopharmaceuticals, Irvine California, to serve as additional contract manufacturer of Hemispherx's Ampligen . Hemispherx Biopharma reaches agreement with Avrio Biopharmaceuticals for the accelerated production of Ampligen .Agreement with Avrio should allow Hemispherx to replenish its Ampligen/Rintatolimod inventory.  Full Article

Hemispherx Biopharma enters into settlement agreements dismissing all pending shareholder derivative litigation
Wednesday, 8 Jun 2016 11:53am EDT 

Hemispherx Biopharma : Hemispherx biopharma enters into settlement agreements dismissing all pending shareholder derivative litigation, resolving disputes with insurance carriers, and obtaining commitments of $3.5 million in payments to company . Two pending disputes in mediation with company insurers have also been settled with a commitment to pay $3,500,000 to company .All four derivative cases have now been settled, subject to final court approval.  Full Article

Hemispherx Biopharma amends and restates agreement with myTomorrows
Monday, 23 May 2016 08:30am EDT 

Hemispherx Biopharma Inc : Hemispherx amends and restates agreement with myTomorrows for the early access program for rintatolimod in Europe . Executed an amended and restated agreement with Impatients, N.V., a Netherlands based company doing business as myTomorrows .MyTomorrows will perform EAP activities in Europe, Turkey to include supply of rintatolimod for treatment of chronic fatigue syndrome.  Full Article

Hemispherx Biopharma qtrly loss per share $0.01
Monday, 16 May 2016 05:09pm EDT 

Hemispherx Biopharma Inc : Hemispherx biopharma announces financial results for the three months ended march 31, 2016 .Quarterly loss per share $0.01.  Full Article

BRIEF-Hemispherx Biopharma says files for resale of 5.4 mln shares of common stock, offered for sale by selling stockholders

* Hemispherx Biopharma - files for resale of of 5.4 million shares of common stock, offered for sale by selling stockholders - SEC Filing‍​ Source text: (http://bit.ly/2yegQEW) Further company coverage: